Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
|Videos|June 2, 2017
Dr. Abida on the Frequency of Mutations in Prostate Cancer
Author(s)Wassim Abida, MD, PhD
Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the frequency of mutations for patients with prostate cancer.
Advertisement
Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the frequency of mutations for patients with prostate cancer.
Many patients with metastatic prostate cancer have an inherited mutation that can be identified through genetic testing, explains Abida.
Some of these mutations can predict a response to specific drugs making this an important area of study, states Abida.
Advertisement
Related to this article
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5